Sword Bio Appoints Michael Losauro as Vice President, Business Development, West Coast
Sword Bio (“Sword”), a contract research organization that supports biotech and pharmaceutical companies with their bioanalytical needs for pre-clinical and clinical trials, announces the appointment of Michael Losauro VP, Business Development West Coast.
Mike joins Sword Bio with more than 20 years of experience driving commercial growth and building strategic partnerships across the biotech and pharmaceutical industries in North America and Europe. Most recently, he served as Senior Director of Strategic Accounts at BioAgilytix, where he worked closely with Sponsors to support critical development programs and deliver high quality bioanalytical solutions. Throughout his career, Mike has been a trusted partner to clients, helping guide complex projects, align scientific capabilities with development goals, and ensure successful execution across key development milestones.
“We’re thrilled to welcome Michael to the team,” said David Dingott, CEO. “Mike brings an exceptional track record of building lasting client partnerships. His unique combination of hands-on scientific experience and commercial leadership gives him a deep understanding of our sponsors’ challenges. Mike knows how to translate complex scientific needs into practical solutions — and how to consistently deliver value beyond expectations.”
“Sword Bio’s commitment to quality, responsiveness, and partnership aligns perfectly with how I build and grow strategic relationships, making this an exciting team to join.” said Mike. “Sponsors today are looking for collaborators who understand both the science and the strategic pressures behind every milestone. I’ve built my career on fostering transparent, solutions-oriented relationships, and I’m eager to strengthen our existing partnerships while forging new ones that support our clients’ long-term growth.”
About Sword
Sword Bio is a leading bioanalytical CRO supporting biotech and pharmaceutical companies with research-grade assays, GLP pre-clinical and clinical assay development, validation, and sample analysis. Our core focus is on PK, Immunogenicity and Biomarker services.
Sword’s team is comprised of industry-experienced scientists and QA experts ensuring the highest levels of science, data integrity, and regulatory compliance through all phases of clinical development.
Sword has built an innovative process that offers its partners minimum lead times, no project minimums, transparency, communication, and white-glove service so that our clients can quickly achieve their goals.
For more information, visit www.swordbio.com